Renal function in African women receiving tenofovir disoproxil fumarate as pre‐exposure prophylaxis for HIV during pregnancy and postpartum: A postpartum safety analysis in the CAP016 randomized control trial
Gaysheen Kistan, Tonya Esterhuizen, Megeshinee Naidoo, Alicia C. Desmond, Motshedisi Sebitloane, Dhayendre Moodley · 2026
Read Renal function in African women receiving tenofovir disoproxil fumarate as pre‐exposure prophylaxis for HIV during pregnancy and postpartum: A postpartum safety analysis in the CAP016 randomized control trial by Gaysheen Kistan, Tonya Esterhuizen, Megeshinee Naidoo, Alicia C. Desmond, Motshedisi Sebitloane, Dhayendre Moodley (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13432447.txt.
Description
Kistan and co-authors check kidney safety of an HIV prevention drug in African women around pregnancy. Tenofovir disoproxil fumarate, used as PrEP, prevents HIV infection in people at risk. Its effect on renal function during pregnancy and after birth has been understudied, despite wide use in women.
The analysis draws on the CAP016 randomised controlled trial. It follows kidney measures in women who took the drug while pregnant and into the postpartum period. Tenofovir can strain kidneys in some users, so pregnancy-specific data matter. Results inform safe PrEP programs for mothers and future pregnancies.
Catalog record
| CREATOR | Gaysheen Kistan, Tonya Esterhuizen, Megeshinee Naidoo, Alicia C. Desmond, Motshedisi Sebitloane, Dhayendre Moodley |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |